Nuvalent, Inc.
NUVLNasdaq
$123.96
↑ +0.0%Jul 14 close · end-of-day
Price
1Y↑ +46.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations.
- CEO
- James R. Porter
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Massachusetts
- Website
- nuvalent.com
Management & directors
- Balcom AlexandraChief Financial Officer
- Lane BenjaminSee Remarks
- Miller Deborah AnnChief Legal Officer
- Noci DarleneChief Development Officer
- Pelish Henry E.Chief Scientific Officer
- Porter James RichardPresident and CEO
- Turner Christopher DurantChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
NUVL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.39↑ +17.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.9M | -$45.8M | -$86.1M | -$149.5M | -$280.4M | -$414.3M |
| Net income | -$14.6M | -$46.3M | -$81.9M | -$126.2M | -$260.8M | -$425.4M |
| Diluted EPS | -$5.08 | -$2.13 | -$1.65 | -$2.17 | -$3.93 | -$5.85 |
| Operating cash flow | -$14.9M | -$40.0M | -$65.0M | -$99.7M | -$185.1M | -$275.2M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$65.2M | -$76.3M | -$86.3M | -$94.8M | -$104.6M | -$112.7M | -$102.2M | -$119.4M |
| Net income | -$57.2M | -$84.3M | -$74.8M | -$84.6M | -$99.7M | -$122.4M | -$118.7M | -$109.3M |
| Diluted EPS | -$0.88 | -$1.28 | -$1.08 | -$1.18 | -$1.39 | -$1.70 | -$1.58 | -$1.39 |
| Operating cash flow | -$41.2M | -$45.8M | -$62.0M | -$54.8M | -$76.6M | -$70.5M | -$73.3M | -$92.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Flynn James E | D | 8,299,225 | $124.00 | $1.0B | filing |
| 2026-07-15 | Flynn James E | D | 8,299,225 | $124.00 | $1.0B | filing |
| 2026-07-15 | Flynn James E | D | 650,000 | $124.00 | $80.6M | filing |
| 2026-07-15 | Porter James Richard· President and CEO | U | 203,529 | $124.00 | $25.2M | filing |
| 2026-07-15 | Balcom Alexandra· Chief Financial Officer | U | 44,433 | $124.00 | $5.5M | filing |
| 2026-07-15 | Turner Christopher Durant· Chief Medical Officer | U | 31,530 | $124.00 | $3.9M | filing |
| 2026-07-15 | Pelish Henry E.· Chief Scientific Officer | U | 22,393 | $124.00 | $2.8M | filing |
| 2026-07-15 | Lane Benjamin· See Remarks | U | 21,092 | $124.00 | $2.6M | filing |
| 2026-07-15 | Miller Deborah Ann· Chief Legal Officer | U | 18,534 | $124.00 | $2.3M | filing |
| 2026-07-15 | Noci Darlene· Chief Development Officer | U | 17,017 | $124.00 | $2.1M | filing |
| 2026-07-15 | Flynn James E | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Wheeler Cameron | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Srivastava Sapna | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Flynn James E | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Protopapas Anna | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Meyers Michael L. | U | 5,146 | $124.00 | $638,104.00 | filing |
| 2026-07-15 | Bogle Grant C. | U | 3,714 | $124.00 | $460,536.00 | filing |
| 2026-07-15 | Flynn James E | D | 3,444 | $124.00 | $427,056.00 | filing |
| 2026-07-15 | Oliger Christy J. | U | 1,324 | $124.00 | $164,176.00 | filing |
| 2026-07-15 | Miller Deborah Ann· Chief Legal Officer | Award | 14,350 | $0.00 | $0.00 | filing |
| 2026-07-15 | Porter James Richard· President and CEO | Award | 40,025 | $0.00 | $0.00 | filing |
| 2026-07-15 | Noci Darlene· Chief Development Officer | Award | 14,350 | $0.00 | $0.00 | filing |
| 2026-07-15 | Balcom Alexandra· Chief Financial Officer | Award | 14,350 | $0.00 | $0.00 | filing |
| 2026-07-15 | Pelish Henry E.· Chief Scientific Officer | Award | 14,350 | $0.00 | $0.00 | filing |
| 2026-07-15 | Lane Benjamin· See Remarks | Award | 7,120 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.